Cancer Information Helpline Call 0800 226 237 Email an Information nurse
Current

Breakthrough therapies and the New Zealand Early Access to Medicines Scheme

Breakthrough therapies and the New Zealand Early Access to Medicines Scheme

It is highly unusual for the Cancer Society to get involved in any national debate around the funding of particular cancer drugs. However, in the case of the new immunotherapies for melanoma, we have made an exception for reasons of equity, evidence and deep concerns about decision processes.

The Cancer Society urges the establishment of an Early Access to Medicines Scheme (EAMS) in New Zealand because of concerns around equity and the current decision-making processes.

To learn more, download our full position statement: